According to a recent study published in the journal Heart, RV afterload increases in patients with chronic thromboembolic pulmonary hypertension (CTEPH) during exercise, resulting in a marked reduction in RVEF and SV reserve. However, sildenafil may reverse this effect. In patients with…
News
Albuquerque-based Respira Therapeutics, Inc. is a biopharmaceutical company currently developing a dry powder inhaler drug delivery technology called AOS-DPI for RT234, a drug that is being designed to address pulmonary hypertension and other respiratory diseases such as IPF and COPD. In an effort to bolster the company’s commercialization efforts, they recently announced that Andy Clark has been appointed…
Results of a new study are shedding light on the emotional and physical impact that IPF has on both patients and caregivers. The new insights could help pave the way for improved patient care, leading to better quality of life for those with the disease. Idiopathic…
Specialty pharmaceutical company SteadyMed Ltd. recently raised $12.2 million in equity financing, co-led by subsidiaries of Federated Investors Inc. and Deerfield Management Company L.P., as well as existing shareholders from the company. The funding will be invested in SteadyMed’s therapeutic product candidates for the treatment of orphan diseases, including…
Researchers at the School of Medicine at Sapienza University of Rome found that Concentric hypertrophy in the heart right ventricle might represent a favorable adaptive pattern to increased afterload in idiopathic pulmonary arterial hypertension. The study, entitled “Right ventricular remodeling in idiopathic pulmonary arterial hypertension: adaptive versus…
The ERS Pulmonary Hypertension Research Award will grant €40,000 to a pair of carefully selected scientists currently pursuing active research projects in the field of pulmonary hypertension, with regard to its pathophysiology, basic science, epidemiology, clinical practice, prevention, treatment, diagnosis or rehabilitation. The awards are reserved exclusively for candidates younger than 45 years old at the time…
Biopharmaceutical company MediciNova recently announced that MN-001 (tipelukast) has been approved for clinical trials by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe idiopathic pulmonary fibrosis (IPF). MN-001 is an orally-available small…
A new study out of Toronto, Canada has evaluated whether rheumatoid arthritis-associated pulmonary arterial hypertension (RA-PAH) is a more severe disease compared to idiopathic pulmonary arterial hypertension (IPAH). Published on January 13, 2015, the study is titled “Survival in rheumatoid arthritis-associated pulmonary arterial hypertension compared…
Earlier in the week, Pulmonary Hypertension News reported on how the drug Bosentan improved Pulmonary Hypertension Secondary to IPF in an individual case study. In a related story, medical researchers from the Academic Medical Center in Amsterdam, Netherlands, are currently recruiting adult patients (>18) with congenital heart…
Cynata Therapeutics Ltd., an Australian regenerative medicine company developing a therapeutic stem cell platform technology called Cymerus™, has announced the launch of a study to evaluate the platform’s efficacy in treating an animal model of pulmonary fibrosis (PF) — a condition that frequently results in pulmonary…
A study published in the journal Respiratory Medicine Case Reports revealed a case where a patient with idiopathic pulmonary fibrosis (IPF) was successfully treated for severe pulmonary hypertension (PH) with bosentan. The study is entitled “Bosentan for…
Despite improved understanding of the etiology of pulmonary arterial hypertension (PAH), the condition remains a severe and progressive disease, ultimately leading to right-sided cardiac failure. It continues to register significant morbidity and early mortality, with estimates showing that 1,000 Americans are diagnosed with PAH per year. Research and clinical advancements over…
